

Anthony T Newall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7581249/publications.pdf>

Version: 2024-02-01

88
papers

4,845
citations

172207

29
h-index

102304

66
g-index

89
all docs

89
docs citations

89
times ranked

8120
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. <i>Lancet, The</i> , 2018, 391, 1285-1300.	6.3	1,870
2	Economic burden of seasonal influenza in the United States. <i>Vaccine</i> , 2018, 36, 3960-3966.	1.7	309
3	Acute myocardial infarction and influenza: a meta-analysis of case-control studies. <i>Heart</i> , 2015, 101, 1738-1747.	1.2	239
4	A systematic review of interventions in primary care to improve health literacy for chronic disease behavioral risk factors. <i>BMC Family Practice</i> , 2012, 13, 49.	2.9	193
5	A Randomized Clinical Trial of Three Options for N95 Respirators and Medical Masks in Health Workers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 960-966.	2.5	153
6	Cost-effectiveness analyses of human papillomavirus vaccination. <i>Lancet Infectious Diseases, The</i> , 2007, 7, 289-296.	4.6	118
7	Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysis. <i>Vaccine</i> , 2018, 36, 3199-3207.	1.7	118
8	Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines. <i>Pharmacoeconomics</i> , 2014, 32, 525-531.	1.7	88
9	Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia. <i>Clinical Infectious Diseases</i> , 2008, 46, 1647-1655.	2.9	79
10	Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. <i>Lancet Public Health, The</i> , 2017, 2, e367-e374.	4.7	72
11	Influenza-related hospitalisation and death in Australians aged 50 years and older. <i>Vaccine</i> , 2008, 26, 2135-2141.	1.7	67
12	The Aetiological Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e69238.	1.1	67
13	Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. <i>Vaccine</i> , 2016, 34, 5442-5448.	1.7	63
14	Global production capacity of seasonal and pandemic influenza vaccines in 2019. <i>Vaccine</i> , 2021, 39, 512-520.	1.7	63
15	The cost-effectiveness of rotavirus vaccination in Australia. <i>Vaccine</i> , 2007, 25, 8851-8860.	1.7	61
16	Influenza-related disease: The cost to the Australian healthcare system. <i>Vaccine</i> , 2008, 26, 6818-6823.	1.7	60
17	Using Economic Evidence to Set Healthcare Priorities in Low-income and Lower-middle-income Countries: A Systematic Review of Methodological Frameworks. <i>Health Economics (United Kingdom)</i> , 2016, 25, 140-161.	0.8	59
18	Which providers can bridge the health literacy gap in lifestyle risk factor modification education: a systematic review and narrative synthesis. <i>BMC Family Practice</i> , 2012, 13, 44.	2.9	57

#	ARTICLE	IF	CITATIONS
19	Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice. <i>Pharmacoeconomics</i> , 2015, 33, 1255-1268.	1.7	56
20	Mortality Attributable to Seasonal and Pandemic Influenza, Australia, 2003 to 2009, Using a Novel Time Series Smoothing Approach. <i>PLoS ONE</i> , 2013, 8, e64734.	1.1	45
21	Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. <i>Vaccine</i> , 2019, 37, A132-A139.	1.7	43
22	Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches. <i>Epidemiology and Infection</i> , 2010, 138, 836-842.	1.0	35
23	Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 834-840.	1.4	35
24	Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study. <i>Epidemiology and Infection</i> , 2015, 143, 2871-2881.	1.0	33
25	Factors associated with influenza vaccination in middle and older aged Australian adults according to eligibility for the national vaccination program. <i>Vaccine</i> , 2015, 33, 3299-3305.	1.7	33
26	Contact Tracing of Tuberculosis: A Systematic Review of Transmission Modelling Studies. <i>PLoS ONE</i> , 2013, 8, e72470.	1.1	33
27	A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 818-825.	1.4	32
28	Knowledge, attitudes and practices of Australian medical students towards influenza vaccination. <i>Vaccine</i> , 2016, 34, 6193-6199.	1.7	32
29	Burden of severe rotavirus disease in Australia. <i>Journal of Paediatrics and Child Health</i> , 2006, 42, 521-527.	0.4	31
30	The potential cost-effectiveness of infant pneumococcal vaccines in Australia. <i>Vaccine</i> , 2011, 29, 8077-8085.	1.7	30
31	Cost-effectiveness analysis of N95 respirators and medical masks to protect healthcare workers in China from respiratory infections. <i>BMC Infectious Diseases</i> , 2017, 17, 464.	1.3	29
32	The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia. <i>Vaccine</i> , 2008, 26, 2142-2153.	1.7	28
33	Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1. <i>Emerging Infectious Diseases</i> , 2010, 16, 224-230.	2.0	27
34	Role of human papillomaviruses in esophageal squamous cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 12-28.	0.7	27
35	Cost Effectiveness of Influenza Vaccination in Older Adults. <i>Pharmacoeconomics</i> , 2009, 27, 439-450.	1.7	26
36	Inaccurate Ascertainment of Morbidity and Mortality due to Influenza in Administrative Databases: A Population-Based Record Linkage Study. <i>PLoS ONE</i> , 2014, 9, e98446.	1.1	25

#	ARTICLE	IF	CITATIONS
37	WHO guide on the economic evaluation of influenza vaccination. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 211-219.	1.5	25
38	Climate variability and salmonellosis in Singapore – A time series analysis. <i>Science of the Total Environment</i> , 2018, 639, 1261-1267.	3.9	25
39	Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. <i>Vaccine</i> , 2017, 35, 345-352.	1.7	23
40	Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States. <i>Vaccine</i> , 2018, 36, 5910-5915.	1.7	22
41	Economic Evaluations of Childhood Influenza Vaccination. <i>Pharmacoeconomics</i> , 2012, 30, 647-660.	1.7	20
42	Comparison of influenza vaccination coverage between immigrant and Australian-born adults. <i>Vaccine</i> , 2016, 34, 6388-6395.	1.7	20
43	Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability. <i>Pharmacoeconomics</i> , 2013, 31, 693-702.	1.7	19
44	The cost-effectiveness of influenza vaccination in elderly Australians: An exploratory analysis of the vaccine efficacy required. <i>Vaccine</i> , 2014, 32, 1323-1325.	1.7	19
45	Changes in seroprevalence to hepatitis A in Victoria, Australia: A comparison of three time points. <i>Vaccine</i> , 2012, 30, 6020-6026.	1.7	18
46	Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. <i>Vaccine</i> , 2014, 32, 759-765.	1.7	16
47	Risk factors for pertussis hospitalizations in Australians aged 45 years and over: A population based nested case-control study. <i>Vaccine</i> , 2015, 33, 5647-5653.	1.7	15
48	Review of economic evaluations of mask and respirator use for protection against respiratory infection transmission. <i>BMC Infectious Diseases</i> , 2015, 15, 413.	1.3	15
49	Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. <i>Vaccine</i> , 2016, 34, 320-327.	1.7	15
50	Rationale and opportunities in estimating the economic burden of seasonal influenza across countries using a standardized WHO tool and manual. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 13-21.	1.5	15
51	Mortality benefits of influenza vaccination in elderly people. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 462-463.	4.6	14
52	Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 425-435.	0.7	14
53	Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. <i>Vaccine</i> , 2018, 36, 6307-6313.	1.7	14
54	The cost and disease burden of pneumonia in general practice in Australia. <i>Vaccine</i> , 2012, 30, 830-831.	1.7	13

#	ARTICLE	IF	CITATIONS
55	Risk factors and burden of acute Q fever in older adults in New South Wales: a prospective cohort study. <i>Medical Journal of Australia</i> , 2015, 203, 438-438.	0.8	13
56	Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. <i>Communicable Diseases Intelligence Quarterly Report</i> , 2007, 31 Suppl, S1-152.	0.6	13
57	Evidence for the aetiology of human papillomavirus in oesophageal squamous cell carcinoma in the Chinese population: a meta-analysis. <i>BMJ Open</i> , 2013, 3, e003604.	0.8	12
58	Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. <i>Vaccine</i> , 2017, 35, 4307-4314.	1.7	12
59	Delay-adjusted age- and sex-specific case fatality rates for COVID-19 in South Korea: Evolution in the estimated risk of mortality throughout the epidemic. <i>International Journal of Infectious Diseases</i> , 2020, 101, 306-311.	1.5	12
60	Use of the letter-based grading information disclosure system and its influence on dining establishment choice in Singapore: A cross-sectional study. <i>Food Control</i> , 2018, 90, 105-112.	2.8	11
61	The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia. <i>Vaccine</i> , 2018, 36, 1265-1271.	1.7	10
62	Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges. <i>Pharmacoeconomics</i> , 2016, 34, 723-731.	1.7	9
63	Effectiveness of Acellular Pertussis Vaccine in Older Adults: Nested Matched Case-control Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 340-350.	2.9	9
64	Control of varicella in the post-vaccination era in Australia: a model-based assessment of catch-up and infant vaccination strategies for the future. <i>Epidemiology and Infection</i> , 2015, 143, 1467-1476.	1.0	7
65	Under-explored assumptions in influenza vaccination models: Implications for the universal vaccination of children. <i>Vaccine</i> , 2012, 30, 5776-5781.	1.7	6
66	Influenza-associated mortality in South Africa, 2009-2013: The importance of choices related to influenza infection proxies. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 54-64.	1.5	6
67	Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage. <i>Vaccine</i> , 2021, 39, 1727-1735.	1.7	6
68	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25494.	1.2	5
69	High healthcare resource utilisation due to pertussis in Australian adults aged 65 years and over. <i>Vaccine</i> , 2020, 38, 3553-3559.	1.7	5
70	Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , 2021, 24, e25690.	1.2	5
71	What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2666-2669.	1.4	4
72	Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. <i>Vaccine</i> , 2018, 36, 2057-2060.	1.7	4

#	ARTICLE	IF	CITATIONS
73	Rotavirus Vaccination Likely to Be Cost Saving to Society in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 1424-1430.	2.9	4
74	Medicare Benefits Schedule data to monitor influenza immunisation in Australian adults. <i>Public Health Research and Practice</i> , 2015, 25, e2541543.	0.7	4
75	The burden of rotavirus gastroenteritis in children presenting to a paediatric hospital. <i>Epidemiology and Infection</i> , 2009, 137, 943-949.	1.0	3
76	Pertussis vaccination in a cohort of older Australian adults following a cocooning vaccination program. <i>Vaccine</i> , 2018, 36, 4157-4160.	1.7	3
77	Financial cost analysis of a strategy to improve the quality of administrative vaccination data in Uganda. <i>Vaccine</i> , 2020, 38, 1105-1113.	1.7	3
78	Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults. <i>PLoS ONE</i> , 2016, 11, e0160446.	1.1	3
79	Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009-2017. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 1082-1090.	1.5	3
80	Assessing the impact of vaccination programmes on burden of disease: Underlying complexities and statistical methods. <i>Vaccine</i> , 2016, 34, 3022-3029.	1.7	2
81	Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017. <i>Vaccine</i> , 2021, 39, 7578-7583.	1.7	2
82	How can early stage economic evaluation help guide research for future vaccines?. <i>Vaccine</i> , 2021, 40, 175-175.	1.7	2
83	Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 391-399.	0.6	2
84	Rapid mapping of the spatial and temporal intensity of influenza. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1307-1312.	1.3	1
85	Estimating pertussis incidence in general practice using a large Australian primary care database. <i>Vaccine</i> , 2021, 39, 4153-4159.	1.7	1
86	Uncertainty and variability in influenza cost-effectiveness models. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 576-577.	0.8	0
87	Authors' Reply to Gandjour: "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines". <i>Pharmacoeconomics</i> , 2014, 32, 1247-1247.	1.7	0
88	Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. <i>Vaccine</i> , 2019, 37, 7534.	1.7	0